BioVaxys Technology Corp. Completes Unsecured Convertible Debenture Offering

BioVaxys Technology Corp., the Canadian biotechnology firm headquartered in Vancouver, has successfully closed a non‑brokered private placement of unsecured convertible debentures, raising an aggregate gross amount of $335,670. The transaction, which was announced and subsequently confirmed on September 16, 2025, marks a notable step in the company’s financing strategy as it continues to advance its vaccine and immunotherapy pipeline.

Key Terms of the Debentures

  • Principal and Maturity: The debentures are unsecured obligations that mature on August 30, 2026.
  • Interest Rate: They carry a fixed 10 % per annum interest rate, payable quarterly. Interest may be settled either in cash or, at the company’s discretion, in common shares of BioVaxys.
  • Conversion Rights: Holders retain the right to convert the principal amount into BioVaxys shares at any time, at their option. Conversion is executed at the closing price of the shares on the Canadian Securities Exchange (CSE) on the day a notice of conversion is received. All accrued and unpaid interest on the converted amount is also settled by issuing shares.
  • Incentive for Early Conversion: For every $1,000 of debentures purchased, participants receive 4,000 units of an additional incentive—likely warrants or options, though the exact nature is not specified in the brief release.

Strategic Context

BioVaxys has been active since its incorporation in 2001, focusing on innovative solutions for infectious diseases and cancer. Its flagship product, VaxMite, is a novel vaccine designed to protect against the lethal form of malaria, Plasmodium falciparum. Beyond this, the company explores broader applications of its technology platform across various therapeutic areas.

The successful completion of this debenture offering provides BioVaxys with additional capital to fund its research and development activities, particularly the progression of VaxMite through clinical stages. The convertible nature of the instruments aligns the interests of investors with the company’s long‑term growth, allowing them to participate in potential equity upside while receiving a fixed income stream.

Market Reaction

At the close of the trading session on September 16, 2025, BioVaxys’ share price settled at $0.24 CAD, within the 52‑week trading range of $0.20 to $0.80. The company’s market capitalization stands at approximately $7,042,204 CAD, reflecting its status as a small‑cap entity in the Canadian biotech sector.

Conclusion

The closure of the unsecured convertible debenture offering underscores BioVaxys Technology Corp.’s continued commitment to advancing its vaccine and immunotherapy portfolio while securing flexible financing options. Investors and analysts will likely watch for how the additional funds are allocated across the company’s pipeline, particularly the next milestones for VaxMite and potential expansions into oncology and other therapeutic areas.